Close Menu

Tekmira

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals announced last week that it has received a $1.5 million milestone payment from ag-bio giant Monsanto.

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week announced that it has received clearance from the US Food and Drug Administration to provide its experimental Ebola drug, called TKM-Ebola, to individuals with confirmed or suspected infections under expanded access protocols.

NEW YORK (GenomeWeb) – Amid the growing outbreak of Ebola virus in West Africa, investors been paying close attention to Tekmira Pharmaceuticals and its Phase I treatment for the hemorrhagic fever, putting the company's shares on a rollercoaster ride in recent months.

Tekmira Pharmaceuticals disclosed that board member Kenneth Galbraith has resigned from the company.
Tekmira said that, to its knowledge, the departure was "not the result of any disagreement with the corporation relating to [its] operations, policies, or practices."

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week announced the publication of data showing that siRNAs targeting the Marburg virus and formulated with its proprietary lipid nanoparticles can completely protect non-human primates from infection.

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week provided an update on its investigational Ebola infection therapy TKM-Ebola, stating that it expects to provide US regulators with the information required to resume clinical testing of the drug by the fourth quarter of this year.

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals announced last week that the US Food and Drug Administration has modified the hold it placed on the use of the company's investigational Ebola drug TKM-Ebola and will permit its use in infected individuals.

Title: RNA Interference Modulators of Hedgehog Signaling and Uses Thereof
Patent Number: 8,802,639
Filed: March 24, 2005

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week said that it is currently amending the protocol of a Phase I trial of its RNAi-based Ebola infection therapy TKM-Ebola after US regulators halted the study amid safety concerns.

Key RNAi Drugs in the Clinic

Premium

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

Pages

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.